- CIMED Company:
Web:cimedremedios.com.br
Composite Interceptive Med - Sciences Laboratories Private Limited, known as CIMED, is a research and development powerhouse in the pharmaceutical industry. Established in 2018, it has its roots in Bangalore, India's IT and biotech hub.
CIMED is dedicated to developing innovative therapeutics, with a particular focus on interceptive medicine. Chronic diseases, which often develop insidiously over years due to genetic, environmental, and lifestyle factors, are a major target. CIMED's approach is revolutionary. Instead of relying solely on traditional, hard - targeting drug development, it has pioneered a soft - targeting poly - molecular strategy. This strategy aims to intercept, slow down, or even reverse the progression of chronic diseases. By doing so, the company hopes to reduce patients' lifelong dependence on synthetic drugs and avoid the complications associated with chronic illnesses.
The company's products are dose - standardized and derived from natural sources. These therapeutics softly target multiple molecular pathways, minimizing toxicity issues that are common with hard - targeting synthetic molecules. CIMED's research also extends to orphan areas of medicine, where there are currently no standard treatment options available.
With a revenue of $1.4 million and a team of 7 employees as of the information available, CIMED combines diverse drug development strategies. It integrates genomic sequencing data with the latest knowledge on the pathophysiology of chronic diseases, applying artificial intelligence to model and engineer solutions. The company's in - silico machine - learning algorithm, along with the decades of clinical experience of its core scientific team, enables it to make impactful decisions and accelerate the drug discovery process. In essence, CIMED is at the forefront of redefining healthcare, striving to optimize the potential of lifestyle modification and regenerative medicine solutions to enable healthy living and aging.
